
Transactions in connection with share buy-back program
Company Announcement
COPENHAGEN, Denmark; February 27,2023 –Genmab A/S (Nasdaq:GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later than March 31, 2023 and comprises up to 220,000 shares.
The following transactions were executed under the program from February 23, 2023, to February 24, 2023:
No. of shares | Average price (DKK) | Total value (DKK) | |
Accumulated through last announcement | -- | -- | |
February 23, 2023 | 12,000 | 2,645.86 | 31,750,320 |
February 24, 2023 | 10,000 | 2,648.18 | 26,481,800 |
Total | 22,000 | 58,232,120 | |
Accumulated under the program | 22,000 | 58,232,120 |
Details of each transaction are included as an appendix to this announcement.
Following these transactions, Genmab holds 565,416 shares as treasury shares, corresponding to 0.86% of the total share capital and voting rights.
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 22, 2023.
About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.
Company Announcement no. 11
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachments
- Appendix_SBBP_specification for Feb 23-24
- 230227_CA11_Transactions in connections with share buyback program - Feb 27 2023
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial3.6.2023 23:00:00 CEST | Press release
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI technology, were associated with longer progression-free survivalStrong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical outcome COPENHAGEN, Denmark, June 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois. The Phase 1 trial successfully met primary endpoints for safety and tolerability of EVX-01 in metastatic melanoma patients
BW Offshore: Short-term contract extension for Espoir Ivoirien3.6.2023 16:39:00 CEST | Press release
Short-term contract extensionfor Espoir Ivoirien BW Offshore has signed a short-term extension for the lease and operation of the FPSO Espoir Ivoirien in order to discuss a potential purchase of the FPSO by the client. The firm period has been extended until 9 June 2023. For further information, please contact: Ståle Andreassen, CFO, +47 91 71 86 55 Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore: BW Offshore engineers innovative floating production solutions. The Company has a fleet of 8 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Jobindex A/S meddeler sin hensigt om afnotering og tilbud fra Danielsen 2 ApS til aktionærerne om køb af deres aktier til 1.900 kr. pr. aktie2.6.2023 20:16:00 CEST | pressemeddelelse
Selskabsmeddelelse nr. 6 / 2023 København, Danmark 2. juni 2023 – Jobindex A/S (“Jobindex” eller “Selskabet”), meddeler, at Jobindex i dag har besluttet at lade Selskabets aktier slette fra handel og officiel notering fra Nasdaq First North Growth Market Denmark (“Nasdaq First North”) og bemyndiget adm. direktør Kaare Danielsen til at indgive anmodning herom til Nasdaq Copenhagen A/S inden den 1. oktober 2023 samt at Danielsen 2 ApS (“Tilbudsgiver”) fremsætter et frivilligt ureguleret offentligt købstilbud på 1.900 kr. pr. aktie (det “Offentlige Købstilbud”) til alle aktionærer i Jobindex med undtagelse af Tilbudsgiver og Selskabet for så vidt angår egne aktier. For aktionærerne i Jobindex A/S betyder dette, at man har valget imellem at: Acceptere det Offentlige Købstilbud, der indebærer en præmie på ca. 8,6% ift. lukkekursen pr. 2. juni 2023 og en præmie på ca. 9,7% ift. de sidste 12 handelsdages volumenvægtede gennemsnitskurs (VWAP); ellerFortsætte uændret som aktionær i Jobindex A/S
Nokia Corporation: Repurchase of own shares on 02.06.20232.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 2 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 02.06.2023 Espoo, Finland – On 2 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,6953.83CEUX1,1353.84AQEU1,6303.81TQEX1,9403.81Total367,4003.83 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and end
BlueCat acquires network infrastructure monitoring and automation platform Indeni2.6.2023 19:00:00 CEST | Press release
Customers will gain an enhanced ability to maintain network resiliency TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), announced today that it has acquired Indeni. Moelis & Company acted as financial advisors to BlueCat. Financial terms were not disclosed, and the deal is subject to regulatory approval. Indeni’s platform helps network operations (NetOps) teams assure the health of their network appliances such as firewalls, load balancers, and secure web proxies. It analyzes device configurations, metrics, and logs through deep domain expertise, codified as knowledge. And it alerts administrators about existing and potential issues, using a global, crowd-sourced knowledge base to identify and recommend remediation steps using automation. Customers using Check Point, Palo Alto Networks, Fortinet, F5, and m